Quarterly report pursuant to Section 13 or 15(d)

Document And Entity Information

Document And Entity Information - shares
6 Months Ended
Jun. 30, 2016
Aug. 08, 2016
Document Information [Line Items]    
Document Type 10-Q  
Amendment Flag true  
Document Period End Date Jun. 30, 2016  
Document Fiscal Year Focus 2016  
Document Fiscal Period Focus Q2  
Entity Registrant Name MOLECULIN BIOTECH, INC.  
Entity Central Index Key 0001659617  
Current Fiscal Year End Date --12-31  
Entity Filer Category Smaller Reporting Company  
Trading Symbol MBRX  
Entity Common Stock, Shares Outstanding   11,254,756
Amendment Description This Amendment No. 1 (“Form 10-Q/A”) to our Quarterly Report on Form 10-Q for the quarter ended June 30, 2016 (“Original Filing”), filed with the U.S. Securities and Exchange Commission (“SEC”) on August 15, 2016, is being filed for the purpose of restating our unaudited consolidated financial statements as of June 30, 2016 and to make corresponding revisions to certain disclosures in the Original Filing. As disclosed in our Form 8-K filed on November 18, 2016, the restatement is the result of an error in the accounting for the business combination of Moleculin, LLC. Our management has determined that there was a control deficiency in our internal control over financial reporting that constitutes a material weakness, as discussed in Part I – Item 4 of this Form 10-Q/A. A material weakness is a deficiency, or combination of control deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the annual or interim consolidated financial statements will not be prevented or detected on a timely basis. For a discussion of management’s consideration of our disclosure controls and procedures and the material weakness identified, see Part I – Item 4 included in this Form 10-Q/A. For reasons discussed above, we are filing this Form 10-Q/A in order to amend the following items in our Original Filing to the extent necessary to reflect the adjustments discussed above and make corresponding revisions to our financial data cited elsewhere in this Form 10-Q/A: 1) Part I, Item 1. Financial Statements (unaudited) 2)Part I, Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations 3) Part I, Item 4. Controls and Procedures 4)Part II, Item 1A. Risk Factors. In accordance with applicable SEC rules, this Form 10-Q/A includes new certifications required by Rule 13a-14 under the Securities Exchange Act of 1934 (“Exchange Act”) from our Chief Executive Officer and our Chief Financial Officer dated as of the date of filing this Form 10-Q/A. This Form 10-Q/A amends and restates in its entirety each section of the Original Filing impacted as a result of the change in presentation, but each section that has been restated is noted in Note 2 to the financial statements. This Form 10-Q/A has not been updated to reflect events occurring after August 15, 2016, the date of the Original Filing. Therefore, this Form 10-Q/A should be read in conjunction with filings we have made with the SEC subsequent to August 15, 2016.